Home | Publications | Regulations | Late Breaking Clinical Trials (LBCT)

Late Breaking Clinical Trials (LBCT)


I. LBCT search

The Council will be in charge of searching for studies which might be potentially of interest for these very important Congress sessions. Council can be assisted in this task by the Congress Scientific Committee and the SAB. This duty includes actively inviting investigators to submit their work for presentation at the ERA annual Congress.


II. Abstract submission and evaluation.

All LBCT abstracts must be submitted and evaluated exactly like regular abstracts but having different timelines and reviewers (timelines are published on the website). The review and selection must be done by the Council members even if the final selection should be done in collaboration with the Chair of the Scientific Committee.

Only the very best abstracts are selected for the special symposium/symposia (normally 1-2 during each Congress) and authors are offered the same benefits as regular Congress speakers (registration + accommodation + travel). The remaining good abstracts, which comply with the requirements below, are selected for e-poster presentations.

It will also be possible to submit LBCT through the regular abstract submission procedure, in fact, if an abstract fits the requirements described below, its author can tick the appropriate box in the regular abstract submission procedure so that it can be evaluated, not only by the regular review system but also by the Council members, for eventual inclusion in the LBCT symposia at the Congress. If the abstract is accepted as a LBCT one the author will be informed accordingly: in any case he/she will not be able to present it twice.


III. Requirements

 LBCT abstracts should comply with these requirements:

  1. A prospective randomised intervention in renal patients (medications, education, dietetics, physiotherapy, etc…), including at least 100 patients; 
  2. A prospective observational study, including at least 500 patients; 
  3. A prospective, randomised intervention in the pathology of rare renal diseases, with no limit on the number of patients enrolled. 
  4. Not previously reported or published. 


Last update: November 2023